The ipamorelin vs sermorelin question comes up constantly because both peptides raise growth hormone, yet they do it through completely different doors. Ipamorelin works on the ghrelin receptor; sermorelin copies a hormone the body already uses to signal the pituitary. That single difference explains why researchers so often study them together rather than as rivals.
The Compound Universe Take: Ipamorelin is a growth-hormone-releasing peptide (GHRP) that activates the ghrelin receptor (GHS-R1a), while sermorelin is a GHRH analog that binds the separate GHRH receptor. They hit two different pathways to the same pituitary cell, which is why they are often combined rather than chosen one-over-the-other. Neither is an approved anti-aging therapy today, and most human data sits at the pilot or diagnostic stage.
New here? Start with the ipamorelin research summary for the single-compound picture, then use this page to compare the two side by side.
What “ipamorelin vs sermorelin” actually compares
Both compounds are growth hormone secretagogues, meaning they prompt the pituitary to release its own growth hormone instead of injecting synthetic hormone directly. The split is in the receptor they use.
Sermorelin is a 29-amino-acid analog of growth-hormone-releasing hormone (GHRH), the shortest fragment that keeps full GHRH activity. It binds the pituitary GHRH receptor. (Evidence tier: Regulatory / Human.)
Ipamorelin is a pentapeptide GHRP that binds the growth hormone secretagogue receptor (GHS-R1a), the same receptor the hunger hormone ghrelin uses. (Evidence tier: Animal with early human data.)
| Attribute | Ipamorelin | Sermorelin |
|---|---|---|
| Class | GHRP (growth hormone secretagogue) | GHRH analog (GHRH 1-29) |
| Receptor / mechanism | Ghrelin receptor, GHS-R1a | GHRH receptor |
| Best studied for | Selective GH release without cortisol spike | Diagnosing and treating GH deficiency |
| Evidence tier | Animal + early human | Human + past regulatory approval |
| Regulatory status (US) | Not FDA-approved (research use) | Formerly FDA-approved (Geref); withdrawn 2009 |
Ipamorelin: the selective ghrelin-receptor peptide
Ipamorelin was described as the first GHRP-receptor agonist with a selectivity for growth hormone release close to that of GHRH itself [1]. In the original characterization, ipamorelin raised plasma growth hormone in animals but did not push ACTH or cortisol above the levels seen with GHRH, even at doses far above the threshold for GH release [1]. (Evidence tier: Animal.)
That selectivity is the reason ipamorelin gets singled out from older GHRPs. Compounds like GHRP-2 and GHRP-6 tend to raise cortisol and prolactin alongside growth hormone; ipamorelin was engineered to avoid that [1].
The GHRP class works by mimicking ghrelin at the GHS-R1a receptor rather than by copying GHRH [2]. Human clinical data on ipamorelin specifically remains thin, so its profile is best read as a clean animal-model signal that has not been carried into large human trials. (Evidence tier: Animal, with limited human exposure.)
Sermorelin: the GHRH analog with a regulatory history
Sermorelin has the deeper clinical paper trail of the two. It was approved in the United States as Geref, first for evaluating pituitary growth hormone output and later for treating idiopathic growth hormone deficiency in children with growth failure [3][5]. (Evidence tier: Regulatory / Human.)
Because it acts through the native GHRH receptor, sermorelin produces growth hormone release in a pulsatile pattern that mirrors normal physiology, which is part of why it was also examined for adult-onset growth hormone insufficiency [4]. (Evidence tier: Human, older literature.)
The important caveat is that Geref is no longer on the US market. The manufacturer stopped production in 2008 as recombinant human growth hormone took over the pediatric market, and the FDA later confirmed the withdrawal was for commercial reasons, not safety or effectiveness [5]. Sermorelin sold today is compounded or research-grade, not the withdrawn approved product.
How they are studied vs. proven
Neither peptide is currently an approved treatment for healthy-adult “optimization,” and that is the honest frame for any ipamorelin vs sermorelin comparison. Sermorelin’s approvals were narrow (diagnosis and pediatric deficiency) and are historical. Ipamorelin’s strongest evidence is preclinical.
This is also why the two show up as a pair. Because GHRH analogs and GHRPs act on two distinct receptors, combining them is a common research design meant to engage both pathways at once rather than to pick a winner. (Evidence tier: Mechanistic rationale.)
Read this before the hype: Ipamorelin is not FDA-approved and is sold “for research use only.” Sermorelin’s approved product was withdrawn from the US market and current supply is compounded or research-grade. This article summarizes published research; it is not medical advice, a dosing guide, or an endorsement of use. Legal status varies by jurisdiction and is changing.
| Compound | Primary mechanism | Evidence maturity | Legal status (US) |
|---|---|---|---|
| Ipamorelin | GHS-R1a (ghrelin receptor) agonist | Animal + limited human | Not FDA-approved |
| Sermorelin | GHRH receptor agonist | Human + former approval | Approved product withdrawn 2009; compounded only |
| CJC-1295 (common stack partner) | Long-acting GHRH analog | Human pilot (healthy adults) | Not FDA-approved |
Which is studied for what
Sermorelin is the one with a defined clinical use case: it was a diagnostic and pediatric growth-hormone-deficiency agent, so its literature centers on measured GH deficiency, not general wellness [3][4]. Ipamorelin’s research value is its receptor selectivity, which makes it a cleaner tool for studying GH release without the cortisol noise of earlier GHRPs [1].
In practice, the more common comparison researchers run is not ipamorelin against sermorelin but a GHRH analog paired with a GHRP. CJC-1295, a longer-acting GHRH analog, raised growth hormone and IGF-1 for several days in a small healthy-adult study, and it is the GHRH partner most often stacked with ipamorelin in the literature [6]. (Evidence tier: Human pilot.)
Key takeaways
- Ipamorelin acts on the ghrelin receptor (GHS-R1a), a different target than sermorelin, which is why the two are complementary rather than interchangeable [1].
- Sermorelin is a GHRH analog that once held FDA approval as Geref for growth hormone deficiency before its 2009 withdrawal [3][5].
- Ipamorelin is prized for selectivity, releasing growth hormone in animal models without the cortisol rise seen with GHRP-2 and GHRP-6 [1].
- CJC-1295 is the GHRH analog most often stacked with ipamorelin, because pairing the two receptor pathways is a standard research design [6].
- Across both compounds, human evidence for healthy-adult use is limited, so each remains research-stage rather than proven therapy.
Frequently asked questions
What is the main difference between ipamorelin and sermorelin?
Ipamorelin is a GHRP that activates the ghrelin receptor (GHS-R1a), while sermorelin is a GHRH analog that binds the GHRH receptor. They stimulate the same pituitary cell through two separate pathways.
Is ipamorelin or sermorelin FDA-approved?
Neither is an approved anti-aging or optimization therapy. Sermorelin’s approved product (Geref) was withdrawn from the US market in 2009 for commercial reasons, and ipamorelin is sold for research use only.
Can ipamorelin and sermorelin be combined?
They target different receptors, so combining a GHRH analog with a GHRP is a common research design. Most published stacking work, however, pairs ipamorelin with CJC-1295 rather than with sermorelin.
Does ipamorelin raise cortisol like older peptides?
In its original characterization, ipamorelin released growth hormone without raising cortisol or ACTH above GHRH-comparable levels, which set it apart from GHRP-2 and GHRP-6.
Why was sermorelin taken off the market?
The manufacturer stopped producing Geref in 2008 as recombinant human growth hormone dominated the pediatric market, and the FDA confirmed the withdrawal was not for safety or effectiveness reasons.
Is the human evidence strong for either peptide?
Sermorelin has the deeper human and regulatory record, mostly in diagnosis and pediatric deficiency. Ipamorelin’s strongest data is preclinical, so both are best treated as research-stage for general use.
The ipamorelin vs sermorelin comparison sits inside the wider growth hormone secretagogue field, where ipamorelin, a selective GHRP that engages the ghrelin receptor (GHS-R1a) without the cortisol rise of GHRP-2 and GHRP-6, contrasts with sermorelin, the GHRH analog that binds the GHRH receptor and once reached FDA approval as Geref, while CJC-1295 extends the GHRH side of the pathway as a long-acting analog frequently paired with a GHRP; Compound Universe tracks each of these compounds against the primary literature so the comparison reflects evidence maturity rather than marketing.
The bottom line on ipamorelin vs sermorelin is that this is less a contest than a map of two receptors: ipamorelin works the ghrelin-receptor route with notable selectivity in animal models, sermorelin works the GHRH route with the deeper human and regulatory history, and both stay research-stage rather than proven for everyday use.
Compare next: sermorelin research summary | how Compound Universe weighs CJC-1295 against ipamorelin
References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PMID 9849822.
- Do growth hormone-releasing peptides act as ghrelin secretagogues? PMID 11322495.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. PMID 18031173.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006. PMC2699646.
- US FDA / Federal Register. Determination that Geref (sermorelin acetate) injection was not withdrawn for reasons of safety or effectiveness. 78 FR (March 4, 2013); NDA 19-863 / NDA 20-443.
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PMID 16352683 / DOI 10.1210/jc.2005-1536.